Shots:

• The P-III (SEQUOIA-HCM) trial evaluates aficamten vs PBO + SoC in a ratio (1:1) in 270 patients with symptomatic obstructive HCM. The trial is based on the P-II (REDWOOD-HCM) trial
• The 1EPs is the change in pVO2 measured by CPET from baseline to 24wk. & the 2EPs includes change from baseline to 12 & 24wk. in KCCQ score, patients with ≥1 class improvement in NYHA functional class, post-Valsalva LVOT-G, change from baseline to 24wk. in total workload during CPET & heart failure symptoms
• Aficamten received BTD from the US FDA & NMPA for the same indication. In preclinical models, the therapy reduced myocardial contractility by binding directly to cardiac myosin at the selective allosteric binding site

 Ref: Globe Newswire | Image: Stat News